STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Nestlé has since the end of 2014 initiated the launch of powder formula with Lactobacillus reuteri Protectis for children above the age of one year. The products will mainly be sold in emerging markets.
For several years, BioGaia and Nestlé have had a fruitful cooperation to develop products with probiotics. The parties have, as previously announced, entered into an agreement signed 30 May 2013 and giving Nestlé the exclusive rights to use BioGaia's patented probiotic strain Lactobacillus reuteri Protectis in an additional range of products. The new product, powder formula for children over the age of one year, is the result of this agreement.
As scientific support for the new range of products are clinical studies, such as Pedro Gutierrez’ study published in 2014 in Pediatrics showing that Lactobacillus reuteri Protectis could prevent infections in children older than one year.
“We are pleased and excited about this cooperation and look forward to working with Nestlé with the launch of the new product with L. reuteri Protectis”, says Peter Rothschild, President of BioGaia.
Latest press releases from BioGaia
2015-01-12 BioGaia signs exclusive agreement in Vietnam
2014-12-11 BioGaia product effective in constipated adults
2014-12-01 BioGaia invests in promising research company
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 10 February 2015, 3:30 pm CET.
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
This information was brought to you by Cision http://news.cision.com